Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Sales (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Sales for 13 consecutive years, with 0.18% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 93.0% to 0.18% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.37%, a 116.0% increase, with the full-year FY2024 number at 0.88%, down 2300.0% from a year prior.
  • Return on Sales was 0.18% for Q3 2025 at Theravance Biopharma, down from 2.09% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 74.46% in Q3 2022 to a low of 5.59% in Q1 2021.
  • A 5-year average of 3.96% and a median of 0.75% in 2024 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: surged 7868bps in 2022, then crashed -7503bps in 2023.
  • Theravance Biopharma's Return on Sales stood at 4.22% in 2021, then soared by 106bps to 0.27% in 2022, then tumbled by -315bps to 0.57% in 2023, then plummeted by -45bps to 0.83% in 2024, then soared by 122bps to 0.18% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Return on Sales are 0.18% (Q3 2025), 2.09% (Q2 2025), and 0.88% (Q1 2025).